For U.S. Healthcare Professionals Only
+|Aa|-
Renvela

Renvela®: the benefits of an effective monotherapy with flexible dosing options1

Renvela dosing

  • Renvela should be taken 3 times a day, as directed with meals.1
  • For patients not taking a phosphate binder
    • Recommended starting dose is 0.8 g to 1.6 g with meals based on serum phosphorus level.1
  • For patients switching to Renvela
    • Renvela tablets and powder may be switched on a gram-for-gram basis (three 800 mg tablets = one 2.4 g packet of powder).1
    • Renagel® (sevelamer hydrochloride) may be switched using the same dose in grams.1
      • The highest daily dose of Renvela studied was 14 grams in CKD patients on dialysis.1
    • Calcium acetate may be switched to Renvela on a tablet-per-tablet basis.1
  • Titrate the Renvela dose by 0.8 g three times daily with meals at 2-week intervals as necessary1
  • Based on clinical studies, the average prescribed daily dose of sevelamer carbonate is approximately 7.2 g per day (3 tablets, 3 times per day with meals).1
  • See Dosing section of Prescribing Information for additional dosing information.

Renvela® for Oral Suspension Powder Video



Indication

Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

Important Safety Information

Sevelamer is contraindicated in patients with bowel obstruction and in patients with known hypersensitivity to sevelamer carbonate or sevelamer hydrochloride or to any of the excipients.

Please see additional Important Safety Information.

Please see full Prescribing Information for Renvela® or full Prescribing Information for Renagel®

Patients eligible for the Medicare Part D Assistance Program could receive Renvela at no cost for the remainder of the calendar year.

Learn more at Renassist.com.

Indication

Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

Important Safety Information

  • Sevelamer is contraindicated in patients with bowel obstruction and in patients with known hypersensitivity to sevelamer carbonate or sevelamer hydrochloride or to any of the excipients.
  • Caution should be exercised in patients with dysphagia, swallowing disorders, and severe gastrointestinal (GI) motility disorders, including severe constipation or major GI tract surgery.
  • Common adverse events reported with sevelamer include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, and constipation. Other events reported include pruritus, rash, fecal impaction and, less commonly, ileus, bowel obstruction, and bowel perforation.
  • Uncommon cases of difficulty swallowing the Renagel or Renvela tablet have been reported. Caution should be exercised in these patients and consideration given to using Renvela suspension in patients with a history of difficulty swallowing.
  • Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take sevelamer.
  • Serum bicarbonate and chloride levels should be monitored.
  • Follow patients for reduced vitamins D, E, and K (coagulation parameters) and folic acid levels.
  • Patients should be informed to take sevelamer with meals and to adhere to their prescribed diets.

Please see full Prescribing Information for Renvela® or full Prescribing Information for Renagel®.
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

Reference:

  1. Data on file, Sanofi US.

Important Safety Information

Sevelamer is contraindicated in patients with bowel obstruction and in patients with known hypersensitivity to sevelamer carbonate or sevelamer hydrochloride or to any of the excipients. Click here to read more.